Amylin Pharmaceuticals Inc. rose the most in 14 months in Nasdaq trading after a competitor to its Byetta diabetes treatment was delayed over side effects.
BusinessWeek.com --, Business Week
Fri, 06/18/2010 - 9:54am
Amylin Pharmaceuticals Inc. rose the most in 14 months in Nasdaq trading after a competitor to its Byetta diabetes treatment was delayed over side effects.